SwedenSweden

Backing for PIGF-blocker

14.08.2008

Lund/Leuven/Basel – Swedish drug development company BioInvent International AB and drug development partner Belgian ThromboGenics NV have entered into a multimillion-euro licensing agreement with Swiss pharma giant Roche. The strategic alliance encompasses the jointly developed anti-cancer agent TB-403, a humanised monoclonal antibody that blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels. TB-403 (Anti-PIGF) has completed its Phase I clinical trial, and recently received approval to enter a Phase Ib dose-escalation trial. TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB) at the University of Leuven (Belgium), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed.
The companies announced in June that BioInvent and ThromboGenics will receive EUR50m in an upfront payment from Roche. In addition, the Swedish and Belgian firms could potentially receive up to a450m over the term of the collaboration. Payments are dependent on the successful completion of a series of development and commercial milestones for multiple indications, as well as royalties on potential product sales, including any backup antibodies based on the inhibition of PIGF. ThromboGenics will receive 60% of the revenue from the deal, while BioInvent will take home 40%. Both firms retain the promotion rights for the antibody in the Nordic, Baltic and Bene-

lux regions. Roche receives a worldwide exclusive license to develop and commercialise the product, and assumes responsibility for all future development costs.

Roche will also provide the two companies with funding for research on non-cancer indications.

SwedenSweden

14.04.2011

Stockholm – Swedish Orphan Biovitrum AB (SOBI) has reported weak results for 2010. The company’s net income declined by 7.7% to SEK1.9bn, with losses for the period totalling up to SEK104m. SOBI spokesmen said that several...

SwedenSweden

06.04.2011

Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR...

SwedenSweden

08.02.2011

Stockholm – At the end of last year, the first European patient was treated with Ruconest – a recombinant C1 esterase inhibitor for the treatment of hereditary acute angioedema attacks developed by the Dutch Pharming Group NV and...

SwedenSweden

10.12.2010

Lund/Jerusalem – Active Biotech’s oral small molecule immunomodulator laquinimod (ABR-215062) has reached the primary endpoint of statistically significant reduction in annualized relapse rate compared to placebo, according to...

SwedenSweden

04.11.2010

Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the...

SwedenSweden

25.10.2010

Stockholm - Swedish researchers have unravelled the three-dimensional structure of the egg receptor, paving the way for new treatments of infertility and novel contraceptives. The team headed by Luca Jovine at Karolinska...

SwedenSweden

16.09.2010

Uppsala – Orexo AB has announced a bold new strategy. The company listed on the Stockholm stock exchange intends to develop and commercialise its own products from now on rather than out-licensing them to international partners....

SwedenSweden

15.09.2010

Linköping – In the first clinical study of its kind, Swedish researchers have proven that biosynthetic corneas can offer a real alternative to rare human replacement corneas. In a process developed by Per Fagerholm and May...

Displaying results 21 to 30 out of 182

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/2/article/backing-for-pigf-blocker.html

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • EPIGENOMICS3.78 EUR11.83%
  • MOLOGEN7.75 EUR6.02%

FLOP

  • SANTHERA92.70 CHF-7.39%
  • MEDIGENE4.40 EUR-2.87%
  • ADDEX3.82 CHF-2.80%

TOP

  • SANTHERA92.70 CHF54.8%
  • EPIGENOMICS3.78 EUR18.1%
  • BB BIOTECH143.70 EUR11.1%

FLOP

  • WILEX2.40 EUR-11.1%
  • BIOFRONTERA2.40 EUR-10.4%
  • VITA 343.77 EUR-9.4%

TOP

  • SANTHERA92.70 CHF3622.9%
  • CO.DON2.45 EUR206.3%
  • PAION2.38 EUR150.5%

FLOP

  • CYTOS0.26 CHF-93.4%
  • THERAMETRICS0.08 CHF-42.9%
  • MERCK KGAA66.43 EUR-42.3%

No liability assumed, Date: 02.09.2014


Current issue

All issues

Product of the week

Products